

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Caroline Ospelt
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2023 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 727** Greetings from the editor 2023/2
J S Smolen

Reviews

- 729** Annals of the Rheumatic Diseases collection on lupus nephritis (2019–2022): novel insights and advances in therapy
M Kostopoulou, A Fanouriakis, G Bertsias, D T Boumpas

- 734** Site of invasion revisited: epigenetic drivers of joint destruction in RA
C Ospelt

Views on news

- 740** At the crossroads of inflammation and fibrosis: epiregulin
S O'Reilly

Recommendations

- 742** 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
G E Fragoulis, E Nikiphorou, M Dey, S S Zhao, D S Courvoisier, L Arnaud, F Atzeni, G Min Behrens, J W J Bijlsma, P Böhm, C A Constantinou, S Garcia-Diaz, M C Kapetanovic, K Lauper, M Luís, J Morel, G Nagy, E Poverino, J van Rompay, M Sebastiani, A Strangfeld, A de Thurah, J Galloway, K L Hyrich

- 754** 2022 EULAR points to consider for the measurement, reporting and application of IFN- γ pathway activation assays in clinical research and practice
J Rodríguez-Carrio, A Burska, P G Conaghan, W A Dik, R Biesen, M-L Eloranta, G Cavalli, M Visser, D T Boumpas, G Bertsias, M Wahren-Herlenius, J Rehwinkel, M-L Frémond, M K Crow, L Rönnblom, M A Versnel, E M Vital

- 763** Instrument selection for the ASAS core outcome set for axial spondyloarthritis
V Navarro-Compán, A Boel, A Boonen, P J Mease, M Dougados, U Kiltz, R B M Landewé, X Baraliakos, W Bautista-Molano, P Chiowchanwisawakit, H Dagfinrud, L Fallon, M Garrido-Cumbrera, I Gensler, B K ElZorkany, N Haroon, Y H Kwan, P M Machado, W Maksymowych, A Molto, N de Peyrecave, D Poddubnyy, M Protopopov, S Ramiro, I-H Song, S van Weely, D van der Heijde

- 773** Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
D Aletaha, A Kerschbaumer, K Kastrati, C Dejaco, M Dougados, I B McInnes, N Sattar, T A Stamm, T Takeuchi, M Trauner, D van der Heijde, M Voshaar, K L Winthrop, A Ravelli, N Bettenidge, G-R R Burmester, J W J Bijlsma, V Bykerk, R Caporali, E H Choy, C Codreanu, B Combe, M K Crow, M de Wit, P Emery, R M Fleischmann, C Gabay, M L Hetland, K L Hyrich, A Iagnocco, J D Isaacs, J M Kremer, X Manette, P A Merkel, E F Mysler, P Nash, M T Nummohamed, K Pavelka, G Poor, A Rubbert-Roth, H Schulze-Koops, A Strangfeld, Y Tanaka, J S Smolen

- 788** Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PRoS-endorsed overarching principles and points-to-consider from an international task force
E M D Smith, A Aggarwal, J Ainsworth, E Al-Abadi, T Avcin, L Bortey, J Burnham, C Ciurtin, C M Hedrich, S Kamphuis, D M Levy, L B Lewandowski, N Maxwell, E F Morand, S Ozen, C E Pain, A Ravelli, C Saad Magalhaes, C A Pilkington, D Schonenberg-Meinema, C Scott, K Tullus, M W Beresford, On behalf of the cSLE T2T International Task Force

Rheumatoid arthritis

- 799** Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage
T Li, C Ge, A Krämer, O Sareila, M Leu Agelii, L Johansson, K Forslind, E Lönnblom, M Yang, B Xu, Q Li, L Cheng, G Bergström, G Fernandez, A Kaslbom, S Rantapää-Dahlqvist, I Gertsson, R Holmdahl

- 809** Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance
S Yamada, Y Nagafuchi, M Wang, M Ota, H Hatano, Y Takeshima, M Okeubo, S Kobayashi, Y Sugimori, N Masahiro, R Yoshida, N Hanata, Y Suwa, Y Tsuchida, Y Iwasaki, S Sumitomo, K Kubo, K Shimane, K Setoguchi, T Azuma, H Kanda, H Shoda, X Zhang, K Yamamoto, K Ishigaki, T Okamura, K Fujio

Psoriatic arthritis

- 820** Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
B Glimtborg, D Di Giuseppe, J K Wallman, D C Nordström, B Gudbjörnsson, M L Hetland, J Askling, G Grondal, T Sökeä, S A Provan, B Michelsen, E K Kristianslund, L Dreyer, T J Love, U Lindström

MORE CONTENTS ►

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>



Member since 2008
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
<http://publicationethics.org/>



When you have finished with this please recycle it

Myositis

- 829** Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis
I Pinal-Fernandez, A Quintana, J C Milisenda, M Casal-Dominguez, S Muñoz-Braceras, A Derfoul, J Torres-Ruiz, K Pak, S Dell'Orso, F Naz, G Gutierrez-Cruz, M Milone, S Shelly, Y Duque-Jaimez, E Tobias-Baraja, A Matas-García, G Garrabou, J Padrosa, J Ros, E Trallero-Araguás, B Walitt, L Christopher-Stine, T E Lloyd, C Zhao, S Swift, A Rajan, J M Grau-Junyent, A Selva-O'Callaghan, T Liewluck, A L Mammen

Vasculitis

- 837** Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
L Ortiz-Fernández, E G Carmona, M Kerick, P Lyons, F D Carmona, R López Mejías, C C Khor, P C Grayson, E Tombetti, L Jiang, H Direskeneli, G Saruhan-Direskeneli, J-L Callejas-Rubio, A Vaglio, C Salvarani, J Hernández-Rodríguez, M C Cid, A W Morgan, P A Merkel, D Burgner, K GC Smith, M A Gonzalez-Gay, A H Sawalha, J Martin, A Marquez

- 848** Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis
S R Henderson, H Horsley, P Frankel, M Khosravi, T Goble, S Carter, M Antonelou, R D R Evans, X Zhang, T-Y Chu, H-H Lin, S Gordon, A D Salama

Treatment

- 857** Efficacy and safety of emapalumab in macrophage activation syndrome
F De Benedetti, A A Grom, P A Brogan, C Bracaglia, M Pardeo, G Marucci, D Eleftheriou, C Papadopoulou, G S Schulert, P Quartier, J Antón, C Laveille, R Frederiksen, V Asnaghi, M Ballabio, P Jacqmin, C de Min

Osteoarthritis

- 866** Increased risk of osteoarthritis in patients with atopic disease
M C Baker, K Sheth, R Lu, D Lu, E P von Kaeppeler, A Bhat, D T Felson, W H Robinson
- 873** Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect
U Styrkarsdottir, L Stefansdottir, G Thorleifsson, O A Stefansson, S Saevarsdottir, S H Lund, T Rafnar, K Hoshijima, K Novak, N Oreiro, I Rego-Perez, C Hansen, N Kazmers, L A Kiemenev, F J Blanco, T Barker, M Kloppenburg, M J Jurynec, D F Gudbjartsson, H Jonsson, U Thorsteinsdottir, K Stefansson

Letters

- 881** BLYS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacept
S Cai, Z Hu, Y Chen, Y Chen, B Ming, R Gao, Z Li, C Ye, J Zhong, L Dong
- 883** Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases
L Wieske, E W Sjalman, P J K van Dam, L Y Kummer, M Steenhuis, Z L E van Kempen, J Killestein, A G Volkers, S W Tas, L Boekeel, G Wolbink, A Van der Kooi, J Raaphorst, M Löwenberg, B Takekenberg, G R A M D'Haens, P I Spuls, M W Bekkenk, A H Musters, N F Post, A L Bosma, M L Hillhorst, Y Vegting, F J Bemelman, A Voskuyl, B Broens, A Parra Sanchez, C A C M van Els, J D Wit, A Rutgers, K de Leeuw, B Horváth, J J G M Verschuuren, A M Ruiter, L van Ouwkerke, D van der Woude, C F Allaart, Y K O Teng, P van Paassen, M H Busch, P B P Jallah, E Brusse, P A van Doorn, A E Baars, D Hijnen, C R G Schreurs, W L Van der Pol, H S Goede, S Keijzer, J Keijser, O Cristianawati, A ten Brinke, N J M Versteegen, K A H Zwinderman, S M van Ham, T W Kuipers, T Risps, F Efimov, On behalf of the T2B! immunity against SARS-CoV-2 study group

Eular news

- 886** News from EULAR
EULAR Communications

Electronic pages

- e128** Correspondence on 'Statistical review: frequently given comments'
D Waki, M Banno, T Fujiwara
- e129** Response to: 'Correspondence on 'Statistical review: frequently given comments'' by Waki *et al*
S Lydersen
- e130** Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'
S K C, S Ahmed, V Shenoy, A R Menon, S Saijan, S AS Babu, P Shenoy
- e131** Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C *et al*
K M D'Silva, N Serling-Boyd, T Y-T Hsu, J A Sparkes, Z S Wallace
- e132** Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'
D Tampe, P Korsten, S Hakroush, M S Winkler, B Tampe
- e133** Response to: 'Correspondence on 'Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab'' by Tampe *et al*
M A Friedman, K L Winthrop

- e134** Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'
A Kaklamanos, P Karamichalos, P G Vlachoyiannopoulos, A G Tzioufas
- e135** Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study' by Kaklamanos *et al*
S Ramiro, R L M Mostard, R B M Landewé
- e136** Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'
R Roongta, A Chattopadhyay, A Ghosh
- e137** Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?' by Roongta *et al*
V F A M Derksen, D van der Woude
- e138** Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'
J T Rosenbaum, M H Weisman, C Shafer, E Aslanyan, R A Howard, K Ogle, H Hamilton, J D Reveille, K L Winthrop, D Choi
- e139** Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Rosenbaum *et al*
K L Hyrich, M Schäfer, A Strangfeld, L Carmona, L Gossec, E F Mateus, S Lawson-Tovey, M Gianfrancesco, P C Robinson, J Yazdany, P M Machado
- e140** Correspondence to: 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco *et al*
R M Flood, R Conway, C Kirby, D Gheta, D J Kane, R H Mullan
- e141** Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'
T-K Lin, L-F Pan, G-P Jong
- e142** Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'
Z Gong, F Zhang
- e143** Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin *et al*
S Abtahi, J H M Driessen, A M Burden, P C Souverein, J P van den Bergh, A Boonen
- e144** Correspondence on 'Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus'
E D Batu, U Kaya Akca, O Basaran, Y Bilginer, S Ozen
- e145** Response to: 'Correspondence on 'Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus' by Batu *et al*
C Adamichou, G Bertias
- e146** Correspondence on: 'What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern'
A Hočevár, A Ambrožič, M Tomšič
- e147** Response to: 'Correspondence on 'What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern' by Hocevar *et al*
P Gauckler, E L Bettac, A Kronbichler
- e148** Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial'
L de Wolff, S Arends, G M Verstappen, A Vissink, F G M Kroese, H Bootsma
- e149** Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial' by de Wolff *et al*
R Felten, J-E Gottenberg
- e150** Correspondence on 'Warfarin use and risk of knee and hip replacements'
C Cheng, F Zhang
- e151** Response to: 'Correspondence on 'Warfarin use and risk of knee and hip replacements' by Cheng and Zhang
T Neogi, C Peloquin, P Ballal, C G Boer
- e152** Paradoxical gastrointestinal effects of interleukin-17 blockers
P Mehta, A Lawrence, A Aggarwal